ING Group’s Esperion Therapeutics ESPR Stock Holding History

ING Group’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-12,352	Closed	-$1.01M	–	600
2015 Q2	$1.01M	Buy	+12,352	New	+$1.21M	0.01%	505

Other funds holding ESPR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

CCI

Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

ING Group's ESPR Position: Q3 2015 in Review

ING Group sold out of Esperion Therapeutics (ESPR) in Q3 2015, closing a stake of 12,352 shares — an estimated $1.01M sold.

ING Group first reported a position in ESPR in Q2 2015 and held it in 1 quarter. The position peaked at $1.01M in Q2 2015. 121 funds tracked by Wall St. Rank hold ESPR as of Q3 2015.

ING Group reported no remaining Esperion Therapeutics position as of Q3 2015 after selling out during the quarter.
ING Group sold 12,352 Esperion Therapeutics shares in Q3 2015, an estimated $1.01M.
ING Group first reported a position in Esperion Therapeutics in Q2 2015 and held it in 1 quarter.
ING Group's Esperion Therapeutics position peaked at $1.01M in Q2 2015.
121 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2015.

Based on ING Group's 13F filing for Q3 2015, filed 10 Nov 2015.